26 Aug SAHPRA and Germany’s GHPP-PharmTrain Project discuss future collaboration
Pretoria, 26 August 2022 – Representatives of the GHPP-PharmTrain Project, part of Germany’s Federal Ministry of Health and located at the Federal Institute for Drugs and Medical Devices (BfArM), visited the South African Health Products Authority (SAHPRA) to discuss future collaboration in capacity-building.
The project has been funded by BfArM since 2019 and is partnering with six regulatory authorities in different Regional Economic Communities in Africa and has provided support in strengthening regulatory structures as well as capacities.
Marketing authorisation of pharmaceuticals for human use is its focus with emphasis on training interventions in clinical assessment (https://ghpp.de/de/projekte/regtrain-pharmtrain/). Within its PT-CoronaGlobal-subproject, SAHPRA has already been partnering with PharmTrain since 2021 (https://ghpp.de/de/projekte/pharmtrain-coronaglobal/).
The goals of this meeting were to exchange ideas, identify needs and create possibilities for further strengthening of regulatory capacities in marketing authorisation of the so-called small molecules as well as of biosimilars between SAHPRA and BfArM in the forthcoming years.
